Medical hypotheses2021,Vol.1461.DOI:10.1016/j.mehy.2020.110357

Perfluorocarbon as an adjuvant for tumor anti-angiogenic therapy: Relevance to hypoxia and HIF-1

Farhadi, Pegah Yarani, Reza Kiani, Sarah Mansouri, Kamran
Medical hypotheses2021,Vol.1461.DOI:10.1016/j.mehy.2020.110357

Perfluorocarbon as an adjuvant for tumor anti-angiogenic therapy: Relevance to hypoxia and HIF-1

Farhadi, Pegah 1Yarani, Reza 2Kiani, Sarah 1Mansouri, Kamran1
扫码查看

作者信息

  • 1. Kermanshah Univ Med Sci, Hlth Technol Inst, Med Biol Res Ctr, Kermanshah, Iran
  • 2. Steno Diabet Ctr Copenhagen, Dept Clin Res, Translat Type 1 Diabet Res, Gentofte, Denmark
  • 折叠

Abstract

Lack of vascularization results in increased demand for oxygen and creates a defined feature of the tumor microenvironment known as tumor hypoxia. It is well established that in response to hypoxia, hypoxia-inducible factor-1 alpha (HIF-1 alpha) is induced which is an important factor in angiogenesis, invasion and metastasis. In turn, HIF1 alpha regulates the expression of angiogenic factors, such as vascular endothelial growth factor (VEGF). Ascribed to abnormal characteristics of tumor angiogenic networks, antiangiogenic therapy approaches can even worsen the hypoxic condition and can create cancer cells with stemness features. Hence oxygen delivery via perfluorocarbon (PFC) to hypoxic sites seems to result in unstable HIF expression and consequent inactivation of angiogenesis cascade and metastasis and therefore, inhibition of cancer cells stemness.

Key words

Angiogenesis/HIF/Antiangiogenic therapy/Cancer stem cell/Perfluorocarbon

引用本文复制引用

出版年

2021
Medical hypotheses

Medical hypotheses

SCI
ISSN:0306-9877
被引量1
参考文献量44
段落导航相关论文